原題
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.

Journal: J Clin Oncol (CiteScore 2022: 39.6)
DOI: 10.1200/JCO-24-02818
PMID: 40408605